Nasus Pharma CEO Joins Board of Directors
Ticker: NSRX · Form: 6-K · Filed: Sep 5, 2025 · CIK: 2029039
| Field | Detail |
|---|---|
| Company | Nasus Pharma LTD (NSRX) |
| Form Type | 6-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
Nasus Pharma CEO Dan Teleman now also a director, replacing David Silberman.
AI Summary
On September 3, 2025, Nasus Pharma Ltd. appointed its CEO, Dan Teleman, to fill a vacancy on its Board of Directors. Mr. Teleman will serve as a Class III director until the 2028 annual general meeting. The Board also resolved to replace David Silberman.
Why It Matters
This appointment may signal a shift in board dynamics or a consolidation of leadership within Nasus Pharma.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment and replacement, with no immediate financial or operational implications.
Key Players & Entities
- Nasus Pharma Ltd. (company) — The company making the filing.
- Dan Teleman (person) — Appointed as CEO and now a director.
- David Silberman (person) — Replaced on the Board.
- September 3, 2025 (date) — Date of the Board's resolution.
- 2028 (date) — Expiration of Dan Teleman's director term.
FAQ
Who was appointed to the Board of Directors of Nasus Pharma Ltd.?
Dan Teleman, the Company's Chief Executive Officer, was appointed to the Board.
On what date was Dan Teleman appointed to the Board?
Dan Teleman was appointed on September 3, 2025.
What is the term of Dan Teleman's directorship?
Mr. Teleman will serve as a Class III director, with his term expiring at the annual general meeting of shareholders to be held in 2028.
Why was Dan Teleman appointed to the Board?
Mr. Teleman was appointed due to a vacancy on the Board, as permitted under the Company's Amended and Restated Articles of Association.
Who was replaced on the Board of Directors?
The Board resolved to replace David Silberman.
Filing Stats: 237 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2025-09-05 08:00:39
Filing Documents
- form6-k.htm (6-K) — 15KB
- 0001493152-25-012675.txt ( ) — 16KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-42796 Nasus Pharma Ltd. Yigal Alon 65 Tel Aviv, Israel 6744317 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On September 3, 2025, the Board of Directors (the “Board”) of Nasus Pharma Ltd. (the “Company”) appointed Dan Teleman, the Company’s Chief Executive Officer, to serve as a director on its Board. Mr. Teleman was appointed to the Board as permitted under the Company’s Amended and Restated Articles of Association due to a vacancy on the Board. Mr. Teleman will serve as a Class III director, which term will expire at the annual general meeting of shareholders to be held in 2028. In addition to Mr. Teleman’s appointment, the Board resolved to replace David Silberman with Ronnie Hershman as a member of the Compensation Committee of the Board. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NASUS PHARMA LTD. Date: September 5, 2025 By: /s/ Dan Teleman Name: Dan Teleman Title: Chief Executive Officer